Pregnancy during enzyme replacement therapy with alglucosidase alfa over a 14-year period in late-onset Pompe disease

被引：0
|
作者：
Yanagihara, Chie [1 ,3 ]
Hayasaka, Yuki [2 ]
Kageyama, Yasufumi [2 ]
机构：
[1] Nishi Kobe Med Ctr, Dept Neurol, Kobe, Japan
[2] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Neurol, Amagasaki, Japan
[3] Nishi Kobe Med Ctr, Dept Neurol, 5-7-1 Koji dai,Nishi ku, Kobe, Japan
来源：
NEUROLOGY AND CLINICAL NEUROSCIENCE | 2023年 / 11卷 / 02期
关键词：
delivery; enzyme replacement therapy; glycogen storage disease type II; Pompe disease; pregnancy;
D O I：
10.1111/ncn3.12695
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We report a female patient who developed Pompe disease at 15 years old and received enzyme replacement therapy (ERT) from 25 years old. After 14 years of treatment, she became pregnant. ERT was suspended during the organogenic period as a precaution and restarted at 15 weeks' gestation. During the pregnancy, there were no complications or respiratory problems, but transient muscle weakness was observed during the third trimester. The patient gave birth by vaginal delivery at 39 weeks' gestation. Eight months postpartum, her muscle weakness had recovered slowly, and the patient was able to stand up without help.
引用
收藏
页码：97 / 99
页数：3
相关论文
共 50 条
  • [1] Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy
    Santos, Miguel Oliveira
    Evangelista, Teresinha
    Conceicao, Isabel
    NEUROMUSCULAR DISORDERS, 2018, 28 (11) : 965 - 968
  • [2] Enzyme replacement therapy with alglucosidase alpha and pregnancy in late-onset Pompe disease
    Santos, M.
    Conceicao, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 688 - 688
  • [3] Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease
    Papadopoulos, Constantinos
    Orlikowsld, David
    Prigent, Helene
    Lacour, Arnaud
    Tard, Celine
    Furby, Alain
    Praline, Julien
    Sole, Guilhem
    Hogrel, Jean-Yves
    De Antonio, Marie
    Semplicini, Claudio
    Deibener-Kaminsky, Joelle
    Kaminsky, Pierre
    Eymard, Bruno
    Taouagh, Nadjib
    Perniconi, Barbara
    Hamroun, Dalil
    Laforet, Pascal
    Bassez, G.
    Bedat-Millet, A. -L.
    Behin, A.
    Eymard, B.
    Leonard -Louis, S.
    Stojkovic, T.
    Canal, A.
    Decostre, V.
    Bouhour, F.
    Boyer, F.
    Caillaud, C.
    Castaing, Y.
    Chapon, F.
    Cintas, P.
    Durieu, I.
    Echaniz-Laguna, A.
    Feasson, L.
    Ferrer, X.
    Froissart, R.
    Piraud, M.
    Germain, D.
    Benistan, K.
    Guffon-Fouilhoux, N.
    Journel, H.
    Labauge, P.
    Levy, A.
    Magot, A.
    Pereon, Y.
    Minot-Myhie, M-C
    Nadaj-Pakleza, A.
    Nathier, C.
    Pellegrini, N.
    MOLECULAR GENETICS AND METABOLISM, 2017, 122 (1-2) : 80 - 85
  • [4] Long-term enzyme replacement therapy with alglucosidase alfa in children and adults with late-onset Pompe disease
    Theunissen, M.
    van Kooten, H.
    Harlaar, L.
    Ismailova, G.
    van den Hout, J.
    Rizopoulos, D.
    Boon, M.
    Brusse, E.
    van Doorn, P.
    van der Ploeg, A.
    van der Beek, N.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S150 - S150
  • [5] Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease
    Papadopoulos, C.
    Orlikowski, D.
    Prigent, H.
    Perniconi, B.
    Taouagh, N.
    Lacour, A.
    Tard, C.
    Furby, A.
    Praline, J.
    Sole, G.
    Semplicini, C.
    Kaminsky, P.
    Eymard, B.
    Hamroun, D.
    Laforet, P.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S109 - S110
  • [6] Enzyme replacement therapy for late-onset Pompe disease
    Dalmia, Sanjush
    Sharma, Reena
    Ramaswami, Uma
    Hughes, Derralynn
    Jahnke, Nikki
    Cole, Duncan
    Smith, Sherie
    Remmington, Tracey
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (12):
  • [7] Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
    Benedikt Schoser
    BMC Musculoskeletal Disorders, 14 (Suppl 2)
  • [8] Enzyme replacement therapy and antibodies in late-onset Pompe disease
    Schneider, I.
    Deschauer, M.
    Hanisch, F.
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2014, 1 : 232 - 234
  • [9] Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease
    Breton Martinez, J. Rafael
    Canovas Martinez, Andres
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 358 (1-2) : 459 - 460
  • [10] Long-term efficacy of alglucosidase alfa in late-onset Pompe disease
    van der Ploeg, Ans
    Clemens, Paula
    Hopkin, Robert J.
    Kacena, Katherine
    Sanson, Bernd-Jan
    Laforet, Pascal
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S134 - S134
12345